NCT03911102已完成2 期
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy, Safety, and Duration of Benefit of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 63
- 试验地点
- 8
- 主要终点
- Percentage of Participants With None or Mild in LCL Severity at Maximum Smile
研究概览
简要总结
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent consistent with International Conference on Harmonisation (ICH)-Good Clinical Practice (GCP) guidelines and local laws, including authorization to release health information, signed prior to any study procedures being performed
- •Be outpatient, male or female subjects, in good general health, 18-65 years old
- •Have a score of moderate (2) or severe (3) LCL at maximum smile effort as assessed by the IGA-LCWS
- •Able to understand the requirements of the study and be willing and able to follow all study procedures, attend all scheduled visits, and successfully complete the study.
排除标准
- •Active skin disease, infections, or inflammation at the injection sites
- •History of clinically significant bleeding disorders
- •Clinically significant laboratory values at screening that may interfere with a subject's ability to complete the study, as determined by the investigator
- •Planned or anticipated need for surgery or hospitalization through the end of the study
- •Pregnant, nursing, or planning a pregnancy during the study; or is Women of Child Bearing Potential (WOCBP) but is not willing to use an effective method of contraception
- •Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to screening through the end of the study
结局指标
主要结局
Percentage of Participants With None or Mild in LCL Severity at Maximum Smile
时间窗: Week 4 After LCL Treatment
Percentage of subjects achieving a score or 0 or 1 (none or mild) in LCL severity at maximum smile at Week 4 after LCL treatment on the Investigator Global Assessment Lateral Canthal Wrinkle Severity (IGA-LCWS) scale
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)Frown LinesNCT03786770Revance Therapeutics, Inc.61
已完成
2 期
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell DiseaseSickle Cell DiseaseNCT00445978BioMarin Pharmaceutical32
已完成
1 期
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)Graft Versus Host DiseaseNCT01379209Regimmune Corporation68
进行中（未招募）
1 期
Gene Transfer Study in Patients With Late Onset Pompe DiseasePompe Disease (Late-onset)NCT04174105Astellas Gene Therapies11
招募中
1 期
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid TumorsAdvanced CancerMetastatic CancerNCT05394103Qurient Co., Ltd.130